Skip to content
DataLookout
Menu

NCT06138028

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

StatusUnknown
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Recruiting
  2. Notable Primary endpoints revised (2)
    • Secondary endpoints revised (2)
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall survival (OS)
Timeframe: up to 24 months
Progression-free survival (PFS)
Timeframe: up to 12 months

Secondary (2)

overall response rate (ORR)
toxicities

Arms and interventions

Combined chemo-immuno-irradiationExperimental

TP regimen plus PD-1 inhibitor for 4 cycles then irradiation and PD-1 inhibitor maintenance therapy for 13 cycles.

Drugs: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors(Sintilimab)

Sites

2 sites in 1 country